Loading clinical trials...

TERMINATEDPHASE2

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323.

NCT00484536•UCB Pharma

View on ClinicalTrials.gov

Summary

The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•relapsing form of MS
•screening EDSS score 0 - 5.5, inclusive
•at least one clinical relapse in the 12 months before screening
•active disease, defined by set of MRI activity criteria
•failed prior treatment with beta-interferons or glatiramer acetate

Exclusion Criteria

•signs of silent infections, including positive tests for HIV1, HIV2 or Hepatitis B or Hepatitis C or tuberculosis
•known allergy to gadolinium-DTPA, and/or ingredients of the study drug formulation
•pre-treatment with immunosuppressive or immunomodulatory drugs prior to screening within certain time frames

Locations (71)

Cullman, Alabama, United States

Phoenix, Arizona, United States

Tucson, Arizona, United States

Springs, Colorado, United States

Washington D.C., District of Columbia, United States

Maitland, Florida, United States

Atlanta, Georgia, United States

Northbrook, Illinois, United States

Fort Wayne, Indiana, United States

Kansas City, Kansas, United States

Key Dates

Start Date

May 1, 2007

Primary Completion Date

November 1, 2009

Completion Date

July 1, 2010

Last Updated

September 12, 2011

Enrollment

232

ACTUAL participants

Conditions

Multiple Sclerosis

Interventions

CDP323

DRUG

placebo

DRUG

CDP323

DRUG

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGNA

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 12, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Intermittent Hypoxia in Persons With Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis